Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 250

The DOI matches its Crossref record.

Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1‐receptor subtype

Open access
Criscione, Leoluca, de Gasparo, Marc, Bühlmayer, Peter, Whitebread, Steven, Ramjoué, Hans‐peter R., Wood, Jeanette·1993·British Journal of Pharmacology

Abstract

The pharmacological profile of valsartan, (S)‐N‐valeryl‐N‐{[2′‐(1H‐tetrazol‐5‐yl)biphenyl‐4‐yl]‐methyl}‐valine, a potent, highly selective, and orally active antagonist at the angiotensin II (AII) AT 1‐receptor, was studied in vitro and in vivo. Valsartan competed with [125 I]‐AII at its specific binding sites in rat aortic smooth muscle cell membranes (AT 1‐receptor subtype) with a Ki of 2.38 n m, but was about 30,000 times less active in human myometrial membranes (AT 2‐receptor subtype). In rabbit aortic rings incubated for 5 min with valsartan, at concentrations of 2, 20 and 200 n m, the concentration‐response curve of AII was displaced to the right and the maximum response was reduced by 33%, 36% and 40%, respectively. Prolongation of the incubation time with valsartan to 1 h or 3 h, further reduced the maximum response by 48% or 59% (after 20 n m) and by 59% or 60% (after 200 n m) respectively. After 3 h incubation an apparent pKB value of 9.26 was calculated. Contractions induced by noradrenaline, 5‐hydroxytryptamine, or potassium chloride were not affected by valsartan. No agonistic effects were observed in the rabbit aorta at concentrations of valsartan up to 2 μ m. In bovine adrenal glomerulosa, valsartan inhibited All‐stimulated aldosterone release without affecting the maximum response (pA 2 8.4). In the pithed rat, oral administration of valsartan (10 mg kg−1) shifted the All‐induced pressor response curves to the right, without affecting responses induced by the electrical stimulation of the sympathetic outflow or by noradrenaline. Animals treated with valsartan 24 h before pithing also showed significant inhibition of the response to AII. In conscious, two‐kidney, one‐clip renal hypertensive rats (2K1C), valsartan decreased blood pressure in a dose‐dependent manner after single i.v. or oral administration. The respective ED 30 values were 0.06 mg kg−1(i.v.) and 1.4 mg kg−1(p.o.). The antihypertensive effect lasted for at least 24 h after either route of administration. After repeated oral administration for 4 days (3 and 10 mg kg−1 daily), in 2K1C renal hypertensive rats, systolic blood pressure was consistently decreased, but heart rate was not significantly affected. In conscious, normotensive, sodium‐depleted marmosets, valsartan decreased mean arterial pressure, measured by telemetry, after oral doses of 1–30 mg kg−1. The hypotensive effect persisted up to 12 h after 3 and 10 mg kg−1 and up to 24 h after 30 mg kg−1. In sodium‐depleted marmosets, the hypotensive effect of valsartan lasted longer than that of losartan (DuP 753). In renal hypertensive rats, both agents had a similar duration (24 h), but a different onset of action (valsartan at 1 h, losartan between 2 h and 24 h). These results demonstrate that valsartan is a potent, specific, highly selective antagonist of AII at the AT 1‐receptor subtype and does not possess agonistic activity. Furthermore, it is an efficacious, orally active, blood pressure‐lowering agent in conscious renal hypertensive rats and in conscious normotensive, sodium‐depleted primates.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1476-5381.1993.tb13877.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 250

Metadata

Authors
Criscione, L., de Gasparo, M., Bühlmayer, P., Whitebread, S., Ramjoué, H. R., & Wood, J.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
1993-10
Volume
110
Issue
2
Pages
761-771
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W2061743585
Cited by
250
References
0
FWCI
8.09
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1‐receptor subtype. https://app.cochat.ai/papers/10.1111/j.1476-5381.1993.tb13877.x
The paper
Criscione, L., de Gasparo, M., Bühlmayer, P., Whitebread, S., Ramjoué, H. R., & Wood, J. (1993). Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1‐receptor subtype. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.1993.tb13877.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.